{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:11:11Z","timestamp":1791803471742,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00105-024-05321-y","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:01:51Z","timestamp":1711008111000},"page":"497-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hidradenitis suppurativa"],"prefix":"10.1007","volume":"75","author":[{"given":"M.","family":"Alter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"issue":"Suppl 5","key":"5321_CR1","first-page":"S1","volume":"10","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis\u00a0CC, Bechara\u00a0FG, Fritz\u00a0K, Kurzen\u00a0H, Likakou\u00a0AI, Marsch\u00a0W, Milling\u00a0A, Nast\u00a0A, Podda\u00a0M, Taube\u00a0KM, Wienert\u00a0V, Winkler\u00a0T (2012) S1-Leitlinie zur Therapie der Hidradenitis suppurativa\/Akne inversa (ICD-10 Ziffer L73.2). JDDG 10(Suppl 5):S1\u2013S31","journal-title":"JDDG"},{"issue":"12","key":"5321_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00105-017-4082-5","volume":"68","author":"R Sabat","year":"2017","unstructured":"Sabat\u00a0R, Tsaousi\u00a0A, Rossbacher\u00a0J, Kurzen\u00a0H, Fadai\u00a0T, Schwichtenberg\u00a0U, Schneider-Burrus\u00a0S (2017) Acne inversa\/hidradenitis suppurativa: an update. Hautarzt 68(12):999\u20131006","journal-title":"Hautarzt"},{"issue":"2","key":"5321_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GBE Jemec","year":"2012","unstructured":"Jemec\u00a0GBE (2012) Hidradenitis suppurativa. N\u00a0Eng J Med 366(2):158\u2013164","journal-title":"N Eng J Med"},{"issue":"2","key":"5321_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1203475417746122","volume":"22","author":"L Scholl","year":"2018","unstructured":"Scholl\u00a0L, Hessam\u00a0S, Bergmann\u00a0U, Bechara\u00a0FG (2018) Surgical treatment of sinus tracts and Fistulas in Perianal Hidradenitis Suppurativa. J\u00a0Cutan Med Surg 22(2):239\u2013241","journal-title":"J Cutan Med Surg"},{"key":"5321_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/120347540300700109","volume":"7","author":"GBE Jemec","year":"2003","unstructured":"Jemec\u00a0GBE (2003) Hidradenitis suppurativa. J\u00a0Cutan Med Surg 7:47\u201356","journal-title":"J Cutan Med Surg"},{"key":"5321_CR6","doi-asserted-by":"crossref","unstructured":"Garg A, Papagermanos V, Midura M, Strunk A (2017) Incidence of hidradenitis suppurativa among tobacco smokers: a\u00a0population based retrospective analysis in the U.S.A. Br J Dermatol","DOI":"10.1111\/bjd.15939"},{"key":"5321_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjd.15255","volume":"176","author":"JR Ingram","year":"2017","unstructured":"Ingram\u00a0JR, Burton\u00a0T (2017) NICE approval of adalimumab for moderate to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics? Br J Dermatol 176:281\u2013282","journal-title":"Br J Dermatol"},{"key":"5321_CR8","doi-asserted-by":"crossref","unstructured":"Wang 9. B, Yang W, Wen W, et\u00a0al.: \u03b3\u2011secretase gene mutations in familial acne inversa. Science 2010; 330: 1065","DOI":"10.1126\/science.1196284"},{"issue":"5","key":"5321_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis\u00a0G, Wolk\u00a0K, Schneider-Burrus\u00a0S, Kalus\u00a0S, Barbus\u00a0S, Gomis-Kleindienst\u00a0S, Sabat\u00a0R (2020) Delayed diagnosis of hidradenitis supurativa and ist effect on patients and healthcare system. Dermatology 236(5):421\u2013430","journal-title":"Dermatology"},{"key":"5321_CR10","volume-title":"Pain in Hidradenitis suppurativa: Data from the PIRANHA-Study. 9 EHSF-Konferenz; 05.\u201307","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis\u00a0G (2020) Pain in Hidradenitis suppurativa: Data from the PIRANHA-Study. 9 EHSF-Konferenz; 05.\u201307. Athen, Griechenland"},{"key":"5321_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1600-0625.2012.01552.x","volume":"21","author":"HH Van der Zee","year":"2012","unstructured":"Van der Zee\u00a0HH, Laman\u00a0JD, Boer\u00a0J, Prens\u00a0EP (2012) Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 21:735\u2013739","journal-title":"Exp Dermatol"},{"issue":"3","key":"5321_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.16019","volume":"178","author":"S Hessam","year":"2018","unstructured":"Hessam\u00a0S, Sand\u00a0M, Gambichler\u00a0T, Skrygan\u00a0M, R\u00fcddel\u00a0I, Bechara\u00a0FG (2018) Interleukin-36 in hidradenitis suppurativa: evidence for a\u00a0distinctive proinflammatory role and a\u00a0key factor in the development of an inflammatory loop. Br J Dermatol 178(3):761\u2013767","journal-title":"Br J Dermatol"},{"issue":"1","key":"5321_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/jdv.16962","volume":"35","author":"S Hessam","year":"2021","unstructured":"Hessam\u00a0S, Gambichler\u00a0T, Skrygan\u00a0M, Scholl\u00a0L, Sand\u00a0M, Meyer\u00a0T, Stockfleth\u00a0E, Bechara\u00a0FG (2021) Increased expression profile of NCSTN, Notch and PI3K\/AKT3 in hidradenitis suppurativa. J\u00a0Eur Acad Dermatol Venereol 35(1):203\u2013210","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5321_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712_1.x","volume":"17","author":"H Kurzen","year":"2008","unstructured":"Kurzen\u00a0H, Kurokawa\u00a0I, Jemec\u00a0GBE et\u00a0al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455\u2013472","journal-title":"Exp Dermatol"},{"key":"5321_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, del Marmol\u00a0V, Mrowietz\u00a0U, Prens\u00a0E, Tzellos\u00a0T, Jemec\u00a0GBE (2015) Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184\u2013190","journal-title":"Dermatology"},{"key":"5321_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","volume":"59","author":"JE Revuz","year":"2008","unstructured":"Revuz\u00a0JE, Canoui-Poitrine\u00a0F, Wolkenstein\u00a0P et\u00a0al (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case control studies. J\u00a0Am Acad Dermatol 59:596\u2013601","journal-title":"J Am Acad Dermatol"},{"key":"5321_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2340\/00015555-1800","volume":"94","author":"CB Kromann","year":"2014","unstructured":"Kromann\u00a0CB, Ibler\u00a0KS, Kristiansen\u00a0VB, Jemec\u00a0GBE (2014) The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 94:553\u2013557","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"5321_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00105-021-04861-x","volume":"72","author":"E Just","year":"2021","unstructured":"Just\u00a0E, Winkler\u00a0T (2021) Acne inversa: eine seltene Erkrankung mit weitreichenden Auswirkungen f\u00fcr Betroffene: Erfahrungen und W\u00fcnsche von Patienten [Acne inversa: A\u00a0rare disease with far-reaching consequences for those affected : Experiences and wishes of patients. Hautarzt 72(8):715\u2013718","journal-title":"Hautarzt"},{"issue":"4","key":"5321_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan\u00a0A, Lynch\u00a0PJ, Eisen\u00a0DB (2009) Hidradenitis suppurativa: a\u00a0comprehensive review. JAAD 60(4):539\u2013561","journal-title":"JAAD"},{"issue":"4","key":"5321_CR20","first-page":"619","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, Desai\u00a0N, Emtestam\u00a0L, Hunger\u00a0RE, Ioannides\u00a0D, Juh\u00e1sz\u00a0I, Lapins\u00a0J, Matusiak\u00a0L, Prens\u00a0EP, Revuz\u00a0EP, Schneider-Burrus\u00a0S, Szepietowski\u00a0JC, Van der Zee\u00a0HH, Jemec\u00a0GBE (2015) European S1 guidline for the treatment of hidradenitis suppurativa\/acne inversa. JEADV 29(4):619\u2013644","journal-title":"JEADV"},{"key":"5321_CR21","volume-title":"Bimekizumab Response Maintenance to 48\u00a0Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase\u00a03, Double-blind, Placebo-Controlled, Randomised Clinical Trials BE HEARD I and II. EADV","author":"JR Ingram","year":"2023","unstructured":"Ingram\u00a0JR, Porter\u00a0M, Chovatiya\u00a0R et\u00a0al (2023) Bimekizumab Response Maintenance to 48\u00a0Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase\u00a03, Double-blind, Placebo-Controlled, Randomised Clinical Trials BE HEARD I and II. EADV (Poster P0086)"},{"key":"5321_CR22","volume-title":"irtuelle Jahrestagung der American Acacemy of Dermatology (AAD)","author":"AB Kimball","year":"2020","unstructured":"Kimball\u00a0AB et\u00a0al (2020) irtuelle Jahrestagung der American Acacemy of Dermatology (AAD). v (Poster # P16480)"},{"issue":"5","key":"5321_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis\u00a0CC, Tzellos\u00a0T, Kyrgidis\u00a0A, Jemec\u00a0GBE, Bechara\u00a0FG, Giamarellos-bourboulis\u00a0EJ, Ingram\u00a0JR, Kanni\u00a0T, Karagianniis\u00a0I, Martorell\u00a0A, Matusiak \u0141, Pinter\u00a0A, Prens\u00a0EP, Presser\u00a0D, Achneider-Burrus\u00a0S, von Stebut\u00a0E, Szepietowski\u00a0JC, van der Zee\u00a0HH, Wilden\u00a0SM, Sabat\u00a0R, European Hidradenitits Suppurativa Foundation Investigator Group, Vekic\u00a0D, de Haes\u00a0P, del Marmol\u00a0V, Alavi\u00a0A, Gulliver\u00a0W, Nassif\u00a0A, Nikolakis\u00a0G, Podda\u00a0M, Antoniou\u00a0C, Delli\u00a0FS, Dessinioti\u00a0C, Patsatsi\u00a0A, Trigoni\u00a0AP, Zisimou\u00a0C, Bettoli\u00a0V, Garcovich\u00a0S, Boer\u00a0J, Horv\u00e1th\u00a0B, Ingvarsson\u00a0G, Puig\u00a0L, Hunger\u00a0RE, Emtestam\u00a0L, Danby\u00a0FW, Kimball\u00a0AB (2017) Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a\u00a0novel dynamic scoring system to assess HS severity. Br J Dermatol 177(5):1401\u20131409","journal-title":"Br J Dermatol"},{"issue":"3","key":"5321_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","volume":"154","author":"S Hessam","year":"2018","unstructured":"Hessam\u00a0S, Scholl\u00a0L, Sand\u00a0M, Schmitz\u00a0L, Reitenbach\u00a0S, Bechara\u00a0FG (2018) A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol 154(3):330\u2013335. https:\/\/doi.org\/10.1001\/jamadermatol.2017.5890","journal-title":"JAMA Dermatol"},{"issue":"3","key":"5321_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th\u00a0B, Janse\u00a0IC, Blok\u00a0JL, Driessen\u00a0RJB, Boer\u00a0J, Mekkes\u00a0JR, Prens\u00a0EP, van der Zee\u00a0HH (2017) Hurley staging refined: a\u00a0proposal by the Dutchhidradenitis suppurativa expert group. Acta Derm Venereol 97(3):412\u2013413","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"5321_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat\u00a0R, Jemec\u00a0GBE, Matusiak \u0141, Kimball\u00a0AB, Prens\u00a0E, Wolk\u00a0K (2020) Hidradenitis suppurativa. Nat Rev Dis Primers 6(1):18","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"5321_CR27","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.3390\/jcm11237240","volume":"11","author":"L Ocker","year":"2022","unstructured":"Ocker\u00a0L, Abu Rached\u00a0N, Seifert\u00a0C, Scheel\u00a0C, Bechara\u00a0FG (2022) Current medical and surgical treatment of hidradenitis suppurativa\u2014a comprehensive review. J\u00a0Clin Med 11(23):7240","journal-title":"J Clin Med"},{"key":"5321_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara\u00a0FG, Podda\u00a0M, Prens\u00a0EP et\u00a0al (2021) Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg 156:1001\u20131009","journal-title":"JAMA Surg"},{"issue":"4","key":"5321_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","volume":"89","author":"P Aarts","year":"2023","unstructured":"Aarts\u00a0P, van Huijstee\u00a0JC, van der Zee\u00a0HH, van Doorn\u00a0MBA, van Straalen\u00a0KR, Prens\u00a0EP (2023) Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a\u00a0randomized controlled trial in a\u00a0real-world setting. J\u00a0Am Acad Dermatol 89(4):677\u2013684","journal-title":"J Am Acad Dermatol"},{"key":"5321_CR30","first-page":"131","volume":"21","author":"L Scholl","year":"2023","unstructured":"Scholl\u00a0L, Schneider-Burrus\u00a0S, Fritz\u00a0B, Sabat\u00a0R, Bechara\u00a0FG (2023) Auswirkungen chirurgischer Eingriffe auf das psychosoziale Wohlbefinden von Patienten mit Hidradenitis suppura. JDDG 21:131\u2013140","journal-title":"JDDG"},{"issue":"5","key":"5321_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2019.08.089","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg\u00a0SR, Strober\u00a0BE, Payette\u00a0MJ (2020) Hidradenitis suppurativa: current and emerging treatments. J\u00a0Am Acad Dermatol 82(5):1061\u20131082","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"5321_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000507323","volume":"236","author":"LAV Orenstein","year":"2020","unstructured":"Orenstein\u00a0LAV, Nguyen\u00a0TV, Damiani\u00a0G, Sayed\u00a0C, Jemec\u00a0GB, Hamzav\u00a0I (2020) Medical and surgical management of hidradenitis suppurativa: a\u00a0review of international treatment guidelines and implementation in general dermatology practice. Dermatology 236(5):393\u2013412","journal-title":"Dermatology"},{"issue":"8","key":"5321_CR33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00105-021-04864-8","volume":"72","author":"P Cramer","year":"2021","unstructured":"Cramer\u00a0P, Schneider-Burrus\u00a0S, Kov\u00e1cs\u00a0M, Scholl\u00a0L, Podda\u00a0M, Bechara\u00a0FG (2021) Hidradenitis suppurativa\/acne inversa-surgical options, reconstruction and combinations with drug therapies\u2014an update. Hautarzt 72(8):692\u2013699","journal-title":"Hautarzt"},{"issue":"2","key":"5321_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/SAP.0000000000000584","volume":"77","author":"MV DeFazio","year":"2016","unstructured":"DeFazio\u00a0MV, Economides\u00a0JM, King\u00a0KS, Han\u00a0KD, Shanmugam\u00a0VK, Attinger\u00a0CE, Evans\u00a0KK (2016) Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa. Ann Plast Surg 77(2):217\u2013222","journal-title":"Ann Plast Surg"},{"issue":"5 Suppl 1","key":"5321_CR35","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","volume":"73","author":"A Mehdizadeh","year":"2015","unstructured":"Mehdizadeh\u00a0A, Hazen\u00a0PG, Bechara\u00a0FG, Zwingerman\u00a0N, Moazenzadeh\u00a0M, Bashash\u00a0M, Sibbald\u00a0RG, Alavi\u00a0A (2015) Recurrence of hidradenitis suppurativa after surgical management: a\u00a0systematic review and meta-analysis. J\u00a0Am Acad Dermatol 73(5 Suppl 1):S70\u2013S77","journal-title":"J Am Acad Dermatol"},{"key":"5321_CR36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","volume":"39","author":"GB Jemec","year":"1998","unstructured":"Jemec\u00a0GB, Wendelboe\u00a0P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 39:971\u2013974","journal-title":"J Am Acad Dermatol"},{"key":"5321_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen\u00a0KR, Tzellos\u00a0T, Guillem\u00a0P et\u00a0al (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a\u00a0prospective European cohort study. J\u00a0Am Acad Dermatol 85:369\u2013378","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5321_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen\u00a0KR, Tzellos\u00a0T, Guillem\u00a0P, Benhadou\u00a0F, Cuenca-Barrales\u00a0C, Daxhelet\u00a0M, Daoud\u00a0M, Efthymiou\u00a0O, Giamarellos-Bourboulis\u00a0EJ, Jemec\u00a0GBE, Katoulis\u00a0AC, Koenig\u00a0A, Lazaridou\u00a0E, Marzano\u00a0AV, Matusiak \u0141, Molina-Leyva\u00a0A, Moltrasio\u00a0C, Pinter\u00a0A, Potenza\u00a0C, Roman\u00ed\u00a0J, Saunte\u00a0DM, Skroza\u00a0N, Stergianou\u00a0D, Szepietowski\u00a0J, Trigoni\u00a0A, Vilarrasa\u00a0E, van der Zee\u00a0HH (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a\u00a0prospective European cohort study. J\u00a0Am Acad Dermatol 85(2):369\u2013378","journal-title":"J Am Acad Dermatol"},{"key":"5321_CR39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jdv.15332","volume":"33","author":"V Bettoli","year":"2019","unstructured":"Bettoli\u00a0V, Manfredini\u00a0M, Massoli\u00a0L et\u00a0al (2019) Rates of antibiotic resistance\/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J\u00a0Eur Acad Dermatol Venereol 33:930\u2013936","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"5321_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball\u00a0AB, Okun\u00a0MM, Williams\u00a0DA, Gottlieb\u00a0AB, Papp\u00a0KA, Zouboulis\u00a0CC, Armstrong\u00a0AW, Kerdel\u00a0F, Gold\u00a0MH, Forman\u00a0SB, Korman\u00a0NJ, Giamarellos-Bourboulis\u00a0EJ, Crowley\u00a0JJ, Lynde\u00a0C, Reguiai\u00a0Z, Prens\u00a0EP, Alwawi\u00a0E, Mostafa\u00a0NM, Pinsky\u00a0B, Sundaram\u00a0M, Gu\u00a0Y, Carlson\u00a0DM, Jemec\u00a0GB (2016) Two phase\u00a03 trials of adalimumab for hidradenitis suppurativa. N\u00a0Engl J Med 375(5):422\u2013434","journal-title":"N Engl J Med"},{"issue":"9","key":"5321_CR41","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","volume":"136","author":"C Hotz","year":"2016","unstructured":"Hotz\u00a0C, Boniotto\u00a0M, Guguin\u00a0A, Surenaud\u00a0M, Jean-Louis\u00a0F, Tisserand\u00a0P, Ortonne\u00a0N, Hersant\u00a0B, Bosc\u00a0R, Poli\u00a0F, Bonnabau\u00a0H, Thi\u00e9baut\u00a0R, Godot\u00a0V, Wolkenstein\u00a0P, Hocini\u00a0H, L\u00e9vy\u00a0Y, H\u00fce\u00a0S (2016) Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J\u00a0Invest Dermatol 136(9):1768\u20131780","journal-title":"J Invest Dermatol"},{"issue":"11","key":"5321_CR42","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","volume":"137","author":"B Moran","year":"2017","unstructured":"Moran\u00a0B, Sweeney\u00a0CM, Hughes\u00a0R, Malara\u00a0A, Kirthi\u00a0S, Tobin\u00a0AM, Kirby\u00a0B, Fletcher\u00a0JM (2017) Hidradenitis suppurativa is characterized by dysregulation of the Th17:treg cell axis, which is corrected by anti-TNF therapy. J\u00a0Invest Dermatol 137(11):2389\u20132395","journal-title":"J Invest Dermatol"},{"issue":"4","key":"5321_CR43","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","volume":"76","author":"\u0141 Matusiak","year":"2017","unstructured":"Matusiak \u0141, Szcz\u0119ch\u00a0J, Bieniek\u00a0A, Nowicka-Suszko\u00a0D, Szepietowski\u00a0JC (2017) Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J\u00a0Am Acad Dermatol 76(4):670\u2013675","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"5321_CR44","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/exd.14619","volume":"31","author":"AB Kimball","year":"2022","unstructured":"Kimball\u00a0AB, Loesche\u00a0C, Prens\u00a0EP, Bechara\u00a0FG, Weisman\u00a0J, Rozenberg\u00a0I, Jarvis\u00a0P, Peters\u00a0T, Roth\u00a0L, Wieczorek\u00a0G, Kolbinger\u00a0F, Jemec\u00a0GBE (2022) IL-17A is a\u00a0pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a\u00a0pre-clinical and phase II proof-of-concept study. Exp Dermatol 31(10):1522\u20131532","journal-title":"Exp Dermatol"},{"issue":"4","key":"5321_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ad.2022.03.030","volume":"114","author":"FJ Melgosa Ramos","year":"2023","unstructured":"Melgosa Ramos\u00a0FJ, Garc\u00eda-Ruiz\u00a0R, Geg\u00fandez Hern\u00e1ndez\u00a0H, Mateu-Puchades\u00a0A (2023) Real-life experience of secukinumab in patients with hidradenitis suppurativa. Actas Dermosifiliogr 114(4):360\u2013362","journal-title":"Actas Dermosifiliogr"},{"issue":"10378","key":"5321_CR46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball\u00a0AB, Jemec\u00a0GBE, Alavi\u00a0A, Reguiai\u00a0Z, Gottlieb\u00a0AB, Bechara\u00a0FG, Paul\u00a0C, Giamarellos Bourboulis\u00a0EJ, Villani\u00a0AP, Schwinn\u00a0A, Ru\u00ebff\u00a0F, Pillay Ramaya\u00a0L, Reich\u00a0A, Lobo\u00a0I, Sinclair\u00a0R, Passeron\u00a0T, Martorell\u00a0A, Mendes-Bastos\u00a0P, Kokolakis\u00a0G, Becherel\u00a0PA, Wozniak\u00a0MB, Martinez\u00a0AL, Wei\u00a0X, Uhlmann\u00a0L, Passera\u00a0A, Keefe\u00a0D, Martin\u00a0R, Field\u00a0C, Chen\u00a0L, Vandemeulebroecke\u00a0M, Ravichandran\u00a0S, Muscianisi\u00a0E (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week\u00a016 and week\u00a052 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase\u00a03\u00a0trials. Lancet 401(10378):747\u2013761","journal-title":"Lancet"},{"key":"5321_CR47","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt\u00a0S, Jemec\u00a0GBE, Forman\u00a0S et\u00a0al (2021) Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a\u00a0phase\u00a02, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol 157:1279\u20131288","journal-title":"JAMA Dermatol"},{"key":"5321_CR48","first-page":"3262","volume-title":"Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: analysis of pooled data from BE HEARD I and\u00a0II phase\u00a03, randomised, double-blind, placebo-controlled, multicentre studies. EADV","author":"CC Zouboulis","year":"2023","unstructured":"Zouboulis\u00a0CC et\u00a0al (2023) Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: analysis of pooled data from BE HEARD I and\u00a0II phase\u00a03, randomised, double-blind, placebo-controlled, multicentre studies. EADV. Oral Presentation, S\u00a03262"},{"key":"5321_CR49","first-page":"3512","volume-title":"IHS4 outcomes with bimekizumab in patients with moderate to severe hidradenitis suppurativa: pooled results from the BE HEARD I and\u00a0II phase\u00a03 trials. EADV","author":"CC Zouboulis","year":"2023","unstructured":"Zouboulis\u00a0CC et\u00a0al (2023) IHS4 outcomes with bimekizumab in patients with moderate to severe hidradenitis suppurativa: pooled results from the BE HEARD I and\u00a0II phase\u00a03 trials. EADV. Oral Presentation, S\u00a03512"},{"key":"5321_CR50","volume-title":"Bimekizumab safety in patients with moderate to severe hidradenitis suppurativa: analysis of pooled data from the BE HEARD I and\u00a0II phase\u00a03, randomised, double-blind, placebo-controlled, multicentre studies. EADV","author":"FG Bechara","year":"2023","unstructured":"Bechara\u00a0FG, Hamzavi\u00a0I, Anadkat\u00a0MJ et\u00a0al (2023) Bimekizumab safety in patients with moderate to severe hidradenitis suppurativa: analysis of pooled data from the BE HEARD I and\u00a0II phase\u00a03, randomised, double-blind, placebo-controlled, multicentre studies. EADV (Poster P0087)"},{"key":"5321_CR51","doi-asserted-by":"crossref","unstructured":"Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML (2023) Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a\u00a0phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J\u00a0Am Acad Dermatol","DOI":"10.1016\/j.jaad.2023.10.034"},{"issue":"8","key":"5321_CR52","first-page":"B5270","volume":"63","author":"C Steenholdt","year":"2016","unstructured":"Steenholdt\u00a0C (2016) Personalized therapy with TNF-inhibitors in crohn\u2019s disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies. Dan Med\u00a0J 63(8):B5270","journal-title":"Dan Med J"},{"issue":"6","key":"5321_CR53","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH van der Zee","year":"2011","unstructured":"van der Zee\u00a0HH, de Ruiter\u00a0L, van den Broecke\u00a0DG, Dik\u00a0WA, Laman\u00a0JD, Prens\u00a0EP (2011) Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a\u00a0rationale for targeting TNF\u2011\u03b1 and IL-1\u03b2. Br J Dermatol 164(6):1292\u20131298","journal-title":"Br J Dermatol"},{"issue":"9","key":"5321_CR54","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/jdv.18175","volume":"36","author":"T Gambichler","year":"2022","unstructured":"Gambichler\u00a0T, Hessam\u00a0S, Cramer\u00a0P, Abu Rached\u00a0N, Bechara\u00a0FG (2022) Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J\u00a0Eur Acad Dermatol Venereol 36(9):1593\u20131596","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"5321_CR55","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jaad.2015.08.052","volume":"73","author":"S Hessam","year":"2015","unstructured":"Hessam\u00a0S, Sand\u00a0M, Gambichler\u00a0T, Bechara\u00a0FG (2015) Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J\u00a0Am Acad Dermatol 73(6):998\u20131005","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"5321_CR56","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jamadermatol.2018.0878","volume":"154","author":"A Garg","year":"2018","unstructured":"Garg\u00a0A, Hundal\u00a0J, Strunk\u00a0A (2018) Overall and subgroup prevalence of crohn disease among patients with hidradenitis suppurativa: a\u00a0population-based analysis in the United States. JAMA Dermatol 154(7):814\u2013818","journal-title":"JAMA Dermatol"},{"issue":"10","key":"5321_CR57","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/ijd.14500","volume":"58","author":"K Phan","year":"2019","unstructured":"Phan\u00a0K, Charlton\u00a0O, Smith\u00a0SD (2019) Hidradenitis suppurativa and metabolic syndrome\u2014systematic review and adjusted meta-analysis. Int J Dermatol 58(10):1112\u20131117","journal-title":"Int J Dermatol"},{"issue":"3","key":"5321_CR58","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3899\/jrheum.130977","volume":"41","author":"P Richette","year":"2014","unstructured":"Richette\u00a0P, Molto\u00a0A, Viguier\u00a0M, Dawidowicz\u00a0K, Hayem\u00a0G, Nassif\u00a0A, Wendling\u00a0D, Aubin\u00a0F, Liot\u00e9\u00a0F, Bachelez\u00a0H (2014) Hidradenitis suppurativa associated with spondyloarthritis\u2014results from a\u00a0multicenter national prospective study. J\u00a0Rheumatol 41(3):490\u2013494","journal-title":"J Rheumatol"},{"issue":"5","key":"5321_CR59","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1159\/000448838","volume":"232","author":"S Schneider-Burrus","year":"2016","unstructured":"Schneider-Burrus\u00a0S, Witte-Haendel\u00a0E, Christou\u00a0D, Rigoni\u00a0B, Sabat\u00a0R, Diederichs\u00a0G (2016) High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa. Dermatology 232(5):606\u2013612","journal-title":"Dermatology"},{"issue":"5","key":"5321_CR60","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.jaad.2018.11.022","volume":"80","author":"S Wertenteil","year":"2019","unstructured":"Wertenteil\u00a0S, Strunk\u00a0A, Garg\u00a0A (2019) Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa. J\u00a0Am Acad Dermatol 80(5):e131\u2013e132","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"5321_CR61","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/j.jaad.2018.11.036","volume":"88","author":"K Kridin","year":"2023","unstructured":"Kridin\u00a0K, Shani\u00a0M, Schonmann\u00a0Y, Fisher\u00a0S, Shalom\u00a0G, Comaneshter\u00a0D, Batat\u00a0E, Cohen\u00a0AD (2023) Psoriasis and hidradenitis suppurativa: a\u00a0large-scale population-based study. J\u00a0Am Acad Dermatol 88(5):e231\u2013e236","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5321_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00403-020-02065-2","volume":"313","author":"N Kirsten","year":"2021","unstructured":"Kirsten\u00a0N, Zander\u00a0N, Augustin\u00a0M (2021) Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 313(2):95\u201399","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"5321_CR63","doi-asserted-by":"publisher","first-page":"e31810","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat\u00a0R, Chanwangpong\u00a0A, Schneider-Burrus\u00a0S, Metternich\u00a0D, Kokolakis\u00a0G, Kurek\u00a0A, Philipp\u00a0S, Uribe\u00a0D, Wolk\u00a0K, Sterry\u00a0W (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 7(2):e31810","journal-title":"PLoS One"},{"issue":"12","key":"5321_CR64","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","volume":"150","author":"IM Miller","year":"2014","unstructured":"Miller\u00a0IM, Ellervik\u00a0C, Vinding\u00a0GR, Zarchi\u00a0K, Ibler\u00a0KS, Knudsen\u00a0KM, Jemec\u00a0GB (2014) Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 150(12):1273\u20131280","journal-title":"JAMA Dermatol"},{"issue":"4","key":"5321_CR65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","volume":"152","author":"A Egeberg","year":"2016","unstructured":"Egeberg\u00a0A, Gislason\u00a0GH, Hansen\u00a0PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429\u2013434","journal-title":"JAMA Dermatol"},{"issue":"4","key":"5321_CR66","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaad.2013.11.014","volume":"70","author":"DA Gold","year":"2014","unstructured":"Gold\u00a0DA, Reeder\u00a0VJ, Mahan\u00a0MG, Hamzavi\u00a0IH (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J\u00a0Am Acad Dermatol 70(4):699\u2013703","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl 1","key":"5321_CR67","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jaad.2015.07.055","volume":"73","author":"JJ Kohorst","year":"2015","unstructured":"Kohorst\u00a0JJ, Kimball\u00a0AB, Davis\u00a0MD (2015) Systemic associations of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 73(5 Suppl 1):S27\u201335","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"5321_CR68","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.3390\/ijms24076596","volume":"24","author":"N Abu Rached","year":"2023","unstructured":"Abu Rached\u00a0N, Gambichler\u00a0T, Ocker\u00a0L, Dietrich\u00a0JW, Quast\u00a0DR, Sieger\u00a0C, Seifert\u00a0C, Scheel\u00a0C, Bechara\u00a0FG (2023) Screening for diabetes mellitus in patients with hidradenitis suppurativa\u2014a monocentric study in Germany. Int J Mol Sci 24(7):6596","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5321_CR69","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/bjd.17578","volume":"180","author":"H Tiri","year":"2019","unstructured":"Tiri\u00a0H, Jokelainen\u00a0J, Timonen\u00a0M, Tasanen\u00a0K, Huilaja\u00a0L (2019) Substantially reduced life expectancy in patients with hidradenitis suppurativa: a\u00a0finnish nationwide registry study. Br J Dermatol 180(6):1543\u20131544","journal-title":"Br J Dermatol"},{"issue":"8","key":"5321_CR70","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00105-021-04851-z","volume":"72","author":"N Kirsten","year":"2021","unstructured":"Kirsten\u00a0N, Frings\u00a0V, Nikolakis\u00a0GD, Presser\u00a0D, Goebeler\u00a0M, Zouboulis\u00a0CC, Augustin\u00a0M (2021) Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa\/acne inversa. Hautarzt 72(8):651\u2013657","journal-title":"Hautarzt"},{"issue":"4","key":"5321_CR71","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13555-020-00401-y","volume":"10","author":"A Pinter","year":"2020","unstructured":"Pinter\u00a0A, Kokolakis\u00a0G, Rech\u00a0J, Biermann\u00a0MHC, H\u00e4berle\u00a0BM, Multimeier\u00a0J, Reinhardt\u00a0M (2020) Hidradenitis suppurativa and concurrent psoriasis: comparison of epidemiologiy, comorbidity profiles, and risk factors. Dermatol Ther (Heidelb) 10(4):721\u2013734","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05321-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05321-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05321-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T12:15:50Z","timestamp":1717503350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05321-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5321"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05321-y","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"14 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.\u00a0Alter<\/b>: A.\u00a0Finanzielle Interessen: Bristol-Myers Squibb; Roche Pharma; Merck Sharp Dohme; Novartis; Merck Serono; Amgen; Pierre Fabre; Sun Pharma; Sanofi\/Regeneron; UCB; Janssen; Pfizer; AbbVie; Incyte. \u2013\u00a0Merck Sharp Dohme; Novartis; UCB; Janssen.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte Dermatologin, Ltd. Ober\u00e4rztin, Klinik f\u00fcr Dermatologie, Johannes-Wesling-Klinikum Minden, Universit\u00e4tsklinik der Ruhr-Universit\u00e4t Bochum.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}